The role of HER2/neu expression and trastuzumab in non-small cell lung cancer

摘要: Research over the past decade has led to an increased understanding of pathophysiology lung cancer. The HER2/neu receptor is a member ErbB family signaling-transduction receptors and appears play major role in development cancer as well many other solid tumors. overexpressed 16% 57% patients with non-small cell (NSCLC) studies have shown that overexpression imparts poor prognosis both resected advanced NSCLC, it does breast Trastuzumab, humanized monoclonal antibody recognizes protein receptor, been approved by US Food Drug Administration for HER2/neu-positive metastatic In NSCLC preclinical studies, marked synergistic growth inhibition occurred when standard cytotoxic chemotherapy was combined trastuzumab HER2/neu-expressing lines. clinical setting, proven safe feasible combination single-institution multi-institutional cooperative group studies. Unlike experience cancer, cardiac toxicity marginal concern this population. However, date, not demonstrable advantage majority patients.